Update app.py

app.py

@@ -16,22 +16,20 @@ st.markdown("Enter the Patent ID, abstract and claims:")
 class SessionState:
     def __init__(self):
         self.patentData = {
-            "1234567890": {
-                "abstract": "A system and method for monitoring and predicting patient health is disclosed. The system utilizes a wearable device that collects data from various sensors, including heart rate, blood pressure, and oxygen saturation. The collected data is analyzed by a machine learning algorithm to predict health issues, such as heart attacks or strokes, before they occur.",
-                "claims": "A method for predicting patient health comprising: collecting data from a wearable device comprising a plurality of sensors that measure heart rate, blood pressure, and oxygen saturation; and analyzing said collected data using a machine learning algorithm to predict potential health issues."
+            "9950112": {
+                "abstract": "The present invention relates to a method of preparing a peptide comprising the amino acid sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO:1). In particular, the method comprises the steps of providing a first peptide fragment having a first protection group, which peptide fragment is conjugated to a support; providing a second peptide fragment having a second protection group; removing the first protection group from the first peptide fragment; and coupling the second peptide fragment to the N-terminally deprotected, support-conjugated first peptide fragment. The present invention further relates to a method of preparing a pharmaceutical composition containing said peptide.",            "claims": "A medication or fluid delivery and control system comprising: (a) at least one apparatus comprising at least one sensor for measuring pharmacodynamic (PD), pharmacokinetic (PK), or both PD and PK parameters in a subject; (b) an infusion device with a rate of infusion which is increased, decreased, or maintained at a given level of infusion based on said PD, PK, or both parameters; and (c) a controller for receiving said PD, PK or both PD and PK parameters and, based on said parameters, increasing, decreasing or maintaining the rate of infusion of said infusion device. 2. The medication or fluid delivery and control system according to claim 1 in which a photoplethysmographic signal is utilized to derive information on the PD and/or PK status of a subject and to control infusion rate in a closed-loop or an open-loop system. 3. The medication or fluid delivery and control system according to claim 2 wherein said photoplethysmographic signal is obtained from the subject's nasal ala as a Single Point of Contact (SPOC) device. 4. The medication or fluid delivery and control system according to claim 1 further comprising any one or a combination of the following elements: 1. a battery pack or access to existing power in the warfighter ensemble 1/1; 2. an accelerometer or other motion sensing device 1/2 worn on the helmet of a subject 1/3 or other location on the head (e.g. behind the subject's ear) which provides signals indicating whether a warfighter is actively moving or is inactive to provide a \u201cwake-up\u201d signal to the sensing system 1/4 so that it may remain in a standby status until needed; 3. at least one, and preferably two SPOC sensor assemblies 3/300 each containing pulse oximeter components (LEDs [photodiodes] 3/301 and photodetector 3/302), nasal pressure or flow sensors, 3/304, optionally, one of two ECG electrodes, 3/305 (the other to be placed in the undergarments or on the torso of the warfighter); 4. means to fix the SPOC sensors securely to the subject, selected from the group consisting of retainer device, 3/306, which fits over the bridge of the subject's nose and/or up to the helmet or other fixation point on the forehead, for example, using a headband, 3/307, wherein the forehead band, 3/307, communications ensemble or the helmet optionally contain reservoirs of medications and or fluids, 3/308, (3/308A, 3/308B, 3/308C, 3/308D, represent separate reservoirs with same or different fluids/medications), each of which is linked (via communication lines 3/308a, 3/308b, 3/308c, 3/308d to and activated for release of fluid/medications by the computer/CPU 3/320 which controls the closed-loop system, and other components/sensors of the system; such that said computer/CPU, 3/320, receives signals, 3/321, from the PD, PK or PD+PK sensors 3/301, 3/302, 3/305, affixed to the subject via communication line(s) 3/301a, 3/302a, 3/305a; 5. a medication or fluid delivery system selected from: a small tube, 3/303, incorporated into the assembly and for emplacement inside the subject's nostril for orientation toward the nasal septum (nasal epithelium/mucosa) which delivers aerosols and/or non-aerosols of pre-metered doses of medications (e.g. opioids, anxiolytics, steroids, vasoactive drugs, and the like); or in alternate configurations, the delivery device comprises a needle/catheter for insertion subcutaneously, rectally, intravenously, intraperitoneally, intraarterially, intracardiacly, intraosseously; 6. where utilized, the intranasal tube, 3/303, or other medication or fluid delivery system connected to a drug delivery system capable of providing aerosolized and/or non-aerosolized medication through the nasal epithelium delivery tube 3/303, said aerosolized and/or non-aerosolized medication(s) optionally stored in pressurized canisters, 3/308, adapted to provide metered doses upon actuation of a valve or a small pump that delivers aerosolized and/or non-aerosolized doses from a given container, 3/308, via delivery line(s) 3/309 connected to said nasal epithelium delivery tube 3/303; 7. optionally, nitric oxide, histamine, methacholine included in the medication delivery system, either as part of the medication compositions or as a separate feed to the nasal mucosa, to increase permeability of the nasal mucosa to the delivered medications; 8. highly concentrated doses of opioids (fentanyl, sufentanyl); opioid antagonists (naltrexone/naloxone for \u201crecovery\u201d if too large a dose of opioids is delivered); vasoactive drugs, particularly vasopressin; steroids (dexamethasone); dissociative agents such as ketamine; anxiolytics (benzodiazepines, gabapentin, pregabalin), included as single component compositions which are separately deliverable to a subject in need of such agents, based on measurements of their PD parameters, provided via separate infusion lines to the subject or may be combined for delivery through a single line; 9. canisters or containers for medications and fluids, 3/308, adapted so that they can be removably but securely inserted into the system (e.g. canisters or container that can be snapped into the system by engaging clips and holding compartments adapted for protection and engagement of such canisters or containers) so that different medication combinations can be provided; 10. a small central processing unit (CPU), 2/210, 3/320, including algorithms/software stored in RAM, 2/220, and/or ROM, 2/230m facilitate closed-loop (servo) delivery of medications and control of the medical devices (sensors and infusion mechanics); 11. small infusion pumps (e.g. ambIT PCA pump, http://www.ambitpump.com), 3/321, deliver volume expanders (hypertonic saline; dextrans) via subcutaneous, intraosseous, or IV routes when available; 12. a second \u201cperipheral\u201d pulse oximeter sensor to provide information on volume status, or the status of an injured extremity; 13. nasal pressure/flow sensors, 3/304, and/or PPG sensors, 3/301, 3/302, utilized to detect phase of respiration and meter doses of medication only during the inspiratory phase; said system to operate as a complete autonomous care by the warfighter, or with the assistance of other warfighters in the combat zone, by emplacing the SPOC sensor assembly if the warfighter is unconscious or unable to apply the assembly to him/herself; or comprising remote communication of the vital sign information and control of the WARCARE\u2122 system once the SPOC is emplaced. 5. The system according to claim 4 wherein said system optionally remains in place as the warfighter is transferred to higher levels of medical care for both monitoring and drug therapy, and, wherein, once IV access is obtained, drug delivery can be switched to this route with said WARCARE\u2122 system optionally remaining in place through all levels of medical care and it being adapted to interface with other medical treatment and monitoring systems. 6. The system according to claim 5, wherein the WARCARE\u2122 assembly is in place as in integral part of the combatant's helmet and/or telemetry/communications gear. 7. The system according to claim 5 wherein the WARCARE\u2122 system delivers medications in a timely manner through nasal epithelium. 8. The system according to claim 5 wherein said accelerometer or like motion and/or orientation detection sensor, monitors whether a warfighter is actively moving or has suddenly ceased to move, or is used to limit the power consumption of the WARCARE\u2122 system by maintaining it in \u201csleep\u201d mode until it senses a sudden change in the war fighter's level of activity. 9. The system according to claim 8 wherein said accelerometer or like motion sensor is adapted to detect very regular but intense body movement indicative of seizure activity, and to the controller to provide a benzodiazepine or other antiseizure medications if the WARCARE\u2122 system is in place or once the SPOC assembly is emplaced by a fellow combatant. 10. A method for delivering medication or fluid to a subject comprising emplacing on said subject a delivery and control system comprising: (a) at least one apparatus comprising at least one sensor for measuring pharmacodynamic (PD), pharmacokinetic (PK), or both PD and PK parameters in a subject; (b) an infusion device with a rate of infusion which is increased, decreased, or maintained at a given level of infusion based on said PD, PK, or both parameters; and (c) a controller for receiving said PD, PK or both PD and PK parameters and, based on said parameters, increasing, decreasing or maintaining the rate of infusion of said infusion device. 11. The method according to claim 10, said delivery control system further comprising any one or a combination of the following elements: 1. a battery pack or access to existing power in the warfighter ensemble 1/1; 2. an accelerometer or other motion sensing device 1/2 worn on the helmet of a subject 1/3 or other location on the head (e.g. behind the subject's ear) which provides signals indicating whether a warfighter is actively moving or is inactive to provide a \u201cwake-up\u201d signal to the sensing system 1/4 so that it may remain in a standby status until needed; 3. at least one, and preferably two SPOC sensor assemblies 3/300 each containing pulse oximeter components (LED photodiodes 3/301 and photodetector 3/302), nasal pressure/flow sensors, 3/304, optionally, one of two ECG electrodes, 3/305 (the other to be placed in the undergarments or on the torso of the warfighter); 4. means to fix the SPOC sensors securely to the subject, selected from the group consisting of retainer device, 3/306, which fits over the bridge of the subject's nose and/or up to the helmet or other fixation point on the forehead, for example, using a headband, 3/307, wherein the forehead band, 3/307, communications ensemble or the helmet optionally contain reservoirs of medications and or fluids, 3/308, (3/308A, 3/308B, 3/308C, 3/308D, represent separate reservoirs with same or different fluids/medications), each of which is linked (via communication lines 3/308a, 3/308b, 3/308c, 3/308d to and activated for release of fluid/medications by the computer/CPU 3/320 which controls the closed-loop system, and other components/sensors of the system; such that said computer/CPU, 3/320, receives signals, 3/321, from the PD, PK or PD+PK sensors 3/301, 3/302, 3/305, affixed to the subject via communication line(s) 3/301a, 3/302a, 3/305a; 5. a medication or fluid delivery system selected from: a small tube, 3/303, incorporated into the assembly and for emplacement inside the subject's nostril for orientation toward the nasal septum (nasal epithelium) which delivers aerosols and/or non-aerosols of pre-metered doses of medications (e.g. opioids, anxiolytics, steroids, vasoactive drugs, and the like); or in alternate configurations, the delivery device comprises a needle for insertion intravenously, intraperitoneally, intracardiacly; 6. where utilized, the intranasal tube, 3/303, or other medication or fluid delivery system connected to a drug delivery system capable of providing aerosolized and/or non-aerosolized medication through the nasal epithelium delivery tube 3/303, said aerosolized and/or non-aerosolized medication(s) optionally stored in pressurized canisters, 3/308, adapted to provide metered doses upon actuation of a valve or a small pump that delivers aerosolized and/or non-aerosolized doses from a given container, 3/308, via delivery line(s) 3/309 connected to said nasal epithelium delivery tube 3/303; 7. optionally, nitric oxide, histamine, methacholine included in the medication delivery system, either as part of the medication compositions or as a separate feed to the nasal mucosa, to increase permeability of the nasal mucosa to the delivered medications; 8. highly concentrated doses of opioids (fentanyl, sufentanyl); opioid antagonists (naltrexone/naloxone for \u201crecovery\u201d if too large a dose of opioids is delivered); vasoactive drugs, particularly vasopressin; steroids (dexamethasone); dissociative agents such as ketamine; anxiolytics (benzodiazepines, gabapentin, pregabalin), included as single component compositions which are separately deliverable to a subject in need of such agents, based on measurements of their PD parameters, provided via separate infusion lines to the subject or may be combined for delivery through a single line; 9. canisters or containers for medications and fluids, 3/308, adapted so that they can be removably but securely inserted into the system (e.g. canisters or container that can be snapped into the system by engaging clips and holding compartments adapted for protection and engagement of such canisters or containers) so that different medication combinations can be provided; 10. a small central processing unit (CPU), 2/210, 3/320, including algorithms/software stored in RAM, 2/220, and/or ROM, 2/230m facilitate closed-loop (servo) delivery of medications and control of the medical devices (sensors and infusion mechanics); 11. small infusion pumps (e.g. ambIT PCA pump, http://www.ambitpump.com), 3/321, deliver volume expanders (hypertonic saline; dextrans) via subcutaneous, intraosseous, or IV routes when available; 12. a second \u201cperipheral\u201d pulse oximeter sensor to provide information on volume status, or the status of an injured extremity; 13. nasal pressure sensors, 3/304, and/or PPG sensors, 3/301, 3/302, utilized to detect phase of respiration and meter doses of medication only during the inspiratory phase; said system to operate as a complete autonomous care by the warfighter, or with the assistance of other warfighters in the combat zone, by emplacing the SPOC sensor assembly if the warfighter is unconscious or unable to apply the assembly to him/herself; or comprising remote communication of the vital sign information and control of the WARCARE\u2122 system once the SPOC is emplaced. 12. The method according to claim 10 to minimize morbidity, mortality, PTSD, TBI, in an injured warfighter which comprises providing to said warfighter, prior to injury, a self-contained system which (i) obtains measurements of the warfighter's vital signs selected from the group consisting of nasal pressure/flow, electrocardiographic signals, blood pressure, heart rate, arrhythmias, respiratory rate, respiratory effort indicative of work of breathing, inspiratory and expiratory breathing ratios (I:E ratios) and patterns of each indicative of normal respiratory or respiratory depression, blood oxygen content, pulse oximetry (SpO2), blood volume measurements including local arterial blood flow amplitude, venous capacitance and comparative flows and capacitance from two or more site indicative of hypovolemia/shock and/or loss of extremity perfusion, pulse transit time, pulse wave velocity and combinations thereof, (ii) processes said measurements to determine the relative state of health or otherwise of the warfighter and, based on said determination, (iii) infuses appropriate medications and fluids into the warfighter in the field as appropriate to the state of health or otherwise of said warfighter. 13. An apparatus comprising: (a) at least one apparatus comprising at least one sensor for measuring pharmacodynamic (PD), pharmacokinetic (PK), or both PD and PK parameters in a subject; (b) an infusion device with a rate of infusion which is increased, decreased, or maintained at a given level of infusion based on said PD, PK, or both parameters; and (c) a controller for receiving said PD, PK or both PD and PK parameters and, based on said parameters, increasing, decreasing or maintaining the rate of infusion of said infusion device. 14. The apparatus according to claim 13 further comprising any one or a combination of the following elements: 1. a battery pack or access to existing power in the warfighter ensemble 1/1; 2. an accelerometer or other motion sensing device 1/2 worn on the helmet of a subject 1/3 or other location on the head (e.g. behind the subject's ear) which provides signals indicating whether a warfighter is actively moving or is inactive to provide a \u201cwake-up\u201d signal to the sensing system 1/4 so that it may remain in a standby status until needed; 3. at least one, and preferably two SPOC sensor assemblies 3/300 each containing pulse oximeter components (LED 3/301 and photodiode 3/302), nasal pressure sensors, 3/304, optionally, one of two ECG electrodes, 3/305 (the other to be placed in the undergarments or on the torso of the warfighter); 4. means to fix the SPOC sensors securely to the subject, selected from the group consisting of retainer device, 3/306, which fits over the bridge of the subject's nose and/or up to the helmet or other fixation point on the forehead, for example, using a headband, 3/307, wherein the forehead band, 3/307, communications ensemble or the helmet optionally contain reservoirs of medications and or fluids, 3/308, (3/308A, 3/308B, 3/308C, 3/308D, represent separate reservoirs with same or different fluids/medications), each of which is linked (via communication lines 3/308a, 3/308b, 3/308c, 3/308d to and activated for release of fluid/medications by the computer/CPU 3/320 which controls the closed-loop system, and other components/sensors of the system; such that said computer/CPU, 3/320, receives signals, 3/321, from the PD, PK or PD+PK sensors 3/301, 3/302, 3/305, affixed to the subject via communication line(s) 3/301a, 3/302a, 3/305a; 5. a medication or fluid delivery system selected from: a small tube, 3/303, incorporated into the assembly and for emplacement inside the subject's nostril for orientation toward the nasal septum (nasal epithelium) which delivers aerosols and/or non-aerosols of pre-metered doses of medications (e.g. opioids, anxiolytics, steroids, vasoactive drugs, and the like); or in alternate configurations, the delivery device comprises a needle for insertion intravenously, intraperitoneally, intracardiacly; 6. where utilized, the intranasal tube, 3/303, or other medication or fluid delivery system connected to a drug delivery system capable of providing aerosolized and/or non-aerosolized medication through the nasal epithelium delivery tube 3/303, said aerosolized and/or non-aerosolized medication(s) optionally stored in pressurized canisters, 3/308, adapted to provide metered doses upon actuation of a valve or a small pump that delivers aerosolized and/or non-aerosolized doses from a given container, 3/308, via delivery line(s) 3/309 connected to said nasal epithelium delivery tube 3/303; 7. optionally, nitric oxide, histamine, methacholine included in the medication delivery system, either as part of the medication compositions or as a separate feed to the nasal mucosa, to increase permeability of the nasal mucosa to the delivered medications; 8. highly concentrated doses of opioids (fentanyl, sufentanyl); opioid antagonists (naltrexone/naloxone for \u201crecovery\u201d if too large a dose of opioids is delivered); vasoactive drugs, particularly vasopressin; steroids (dexamethasone); dissociative agents such as ketamine; anxiolytics (benzodiazepines, gabapentin, pregabalin), included as single component compositions which are separately deliverable to a subject in need of such agents, based on measurements of their PD parameters, provided via separate infusion lines to the subject or may be combined for delivery through a single line; 9. canisters or containers for medications and fluids, 3/308, adapted so that they can be removably but securely inserted into the system (e.g. canisters or container that can be snapped into the system by engaging clips and holding compartments adapted for protection and engagement of such canisters or containers) so that different medication combinations can be provided; 10. a small central processing unit (CPU), 2/210, 3/320, including algorithms/software stored in RAM, 2/220, and/or ROM, 2/230m facilitate closed-loop (servo) delivery of medications and control of the medical devices (sensors and infusion mechanics); 11. small infusion pumps (e.g. ambIT PCA pump, http://www.ambitpump.com), 3/321, deliver volume expanders (hypertonic saline; dextrans) via subcutaneous, intraosseous, or IV routes when available; 12. a second \u201cperipheral\u201d pulse oximeter sensor to provide information on volume status, or the status of an injured extremity; 13. nasal pressure sensors, 3/304, and/or PPG sensors, 3/301, 3/302, utilized to detect phase of respiration and meter doses of medication only during the inspiratory phase; said system to operate as a complete autonomous care by the warfighter, or with the assistance of other warfighters in the combat zone, by emplacing the SPOC sensor assembly if the warfighter is unconscious or unable to apply the assembly to him/herself; or comprising remote communication of the vital sign information and control of the WARCARE\u2122 system once the SPOC is emplaced. 15. The Single Point of Contact (SPOC) system according to claim 3 comprising a PD, PK, or PD and PK acquisition subsystem for emplacement on a subject, a controller unit for receiving signals from said PD, PK, or PD and PK acquisition subsystem and for processing said signals and, on the basis of such processing, controlling the delivery of agents to the subject and an agent delivery subsystem. 16. The SPOC system according to claim 15 in which any or a combination of the following elements is included: a. the PD acquisition subsystem comprises at least one sensor selected from the group consisting of a nasal pressure sensor, a PPG sensor, ECG sensor and combinations thereof; b. the agent delivery subsystem is physically integral with the PD acquisition subsystem, wherein said agent delivery subsystem comprises a fluid or gas channel for delivery of agent to the nasal epithelium and said PD acquisition subsystem comprises a PPG and a nasal pressure sensor."
             },
-            "2345678901": {
-                "abstract": "A software application for real-time translation and transcription of audio recordings is disclosed. The application comprises a speech recognition module that transcribes audio recordings in one language and a machine translation module that translates the transcribed text into another language.",
-                "claims": "A software application for real-time translation and transcription of audio recordings comprising: a speech recognition module configured to transcribe audio recordings in a first language; and a machine translation module configured to translate said transcribed text into a second language."
+            "9604242": {
+                "abstract": "A volatile liquid droplet dispenser for containing a liquid to be dispensed, with a first substrate having a space for containing the liquid, and having an outlet With at least one outlet nozzle, the first substrate further having the space adjacent to the liquid outlet, to receive the liquid such that the liquid may exit through at least one outlet nozzle of the outlet, a second substrate having a liquid inlet, and an actuating membrane arranged to actuate liquid in the space. The first substrate also has a fluidic channel interconnected to the space and arranged to laterally connect the liquid inlet means to the space, thereby conveying the liquid to the space by way of lateral capillary action. The outlet is eccentric to the liquid inlet and in a vertical plane that is substantially the same or lower than the plane of the liquid inlet, depending on the liquid used.",
+                "claims": "Volatile liquid droplet dispenser device for containing a liquid substance to be dispensed, the device comprising: a first substrate having a space for containing said liquid substance, and having liquid outlet means, said liquid outlet means comprising at least one outlet nozzle for ejecting liquid substance there through, said first substrate further having said space arranged proximate to said liquid outlet means and to receive said liquid substance such that said liquid substance may exit the space of the device by traversing said at least one outlet nozzle of said liquid outlet means; a second substrate having a liquid inlet means for allowing said liquid substance to enter said device; an actuating membrane arranged to actuate liquid substance in said space such that the liquid substance undergoes a vibration and contacts the liquid outlet means thereby exiting said device as a liquid droplet spray, wherein said first substrate further comprises a fluidic channel interconnected to said space and arranged to laterally connect said liquid inlet means to said space thereby conveying said liquid substance to said space by way of lateral capillary action; and said liquid outlet means is arranged eccentric to said liquid inlet means and in a vertical plane that is substantially the same or lower than the plane of the liquid inlet means depending on liquid substance properties. 2. Volatile liquid droplet dispenser device according to claim 1, further comprising a first reservoir for containing said liquid substance. 3. Volatile liquid droplet dispenser device according to claim 2, wherein said first reservoir is an external reservoir, and wherein said first substrate or said second substrate further comprises connection means arranged to receive said external reservoir. 4. Volatile liquid droplet dispenser device according to claim 2, wherein said first reservoir is an internal reservoir integrated into said volatile liquid droplet dispenser device. 5. Volatile liquid droplet dispenser device according to claim 1, wherein said first substrate has a recess in a first main surface, which constitutes a space for containing said liquid substance. 6. Volatile liquid droplet dispenser device according to claim 4, wherein said first substrate has a recess in a first main surface, which constitutes a space for containing said liquid substance; and wherein said space is arranged to contain said internal reservoir. 7. Volatile liquid droplet dispenser device according to claim 5, wherein said first substrate further has a through hole traversing said recess and the other main surface of said first substrate, and wherein said liquid outlet means are arranged in said through hole so as to delimit said recess in said first main surface thus closing said through hole. 8. Volatile liquid droplet dispenser device according to claim 1, wherein said actuating membrane is arranged in between the first and second substrates and delimits said space. 9. Volatile liquid droplet dispenser device according to claim 1, wherein said liquid outlet means has a nozzle body including a thicker main section and a thinner membrane section, said thinner membrane section comprising said at least one outlet nozzle. 10. Volatile liquid droplet dispenser device according to claim 1, wherein said liquid outlet means consists of a flat substrate comprising said at least one outlet nozzle. 11. Volatile liquid droplet dispenser device according to claim 1, further comprising a programmable microcontroller for controlling said actuating membrane by varying an operating frequency, and by varying a supply voltage, wherein the operating frequency range and the supply voltage are chosen to correspond to a range of viscosities and a particular droplet size. 12. Volatile liquid droplet dispenser device according to claim 1, wherein said fluidic channel comprises a wick. 13. Volatile liquid droplet dispenser device according to claim 1, wherein said fluidic channel is a metal plate. 14. Volatile liquid droplet dispenser device according to claim 5, wherein said fluidic channel contains a plurality of micro-channels arranged in the first main surface of said first substrate. 15. Volatile liquid droplet dispenser device according to claim 1, wherein said fluidic channel also comprises a buffer reservoir. 16. Volatile liquid droplet dispenser device according to claim 1, wherein said liquid inlet means comprises a wick. 17. Volatile liquid droplet dispenser device according to claim 3, wherein said liquid inlet means is a tube arranged to extend into the external reservoir. 18. Volatile liquid droplet dispenser device according to claim 1, wherein said actuating membrane is formed of a first part and a second part that are arranged in a slideable arrangement with respect to each other. 19. Volatile liquid droplet dispenser device according to claim 3, wherein said external reservoir comprises a collapsible bag linked to said liquid inlet means. 20. Volatile liquid droplet dispenser device according to claim 1, further comprising a venting means. 21. Volatile liquid droplet dispenser device according to claim 11, further comprising a venting means; and wherein said programmable microcontroller is further arranged to actuate said actuating membrane in a bubble-eliminating mode for driving any air bubbles contained in the liquid substance towards said venting means by applying bursts at a frequency of a few to several times higher than the normal operating frequency and with a duration from under 1 second to several seconds. 22. (canceled) 23. Apparatus comprising a volatile droplet dispenser device according to claim 1, wherein said apparatus is selected from the group of a vacuum-cleaner, a floor cleaner, robotics to clean a room, an aromatherapy apparatus, a respiratory therapy apparatus, an air-freshener, a fragrancer, an air purifier, an air conditioner, an insecticide dispensing apparatus, an ironing machine, a white goods appliance or an individual communication apparatus.",
             },
-            "3456789012": {
-                "abstract": "A system and method for energy management in commercial buildings is disclosed. The system utilizes a combination of sensors, energy storage devices, and control algorithms to monitor and optimize energy consumption. The system is designed to reduce energy waste and improve the efficiency of HVAC and lighting systems in commercial buildings.",
-                "claims": "A system for energy management in commercial buildings comprising: a plurality of sensors configured to measure temperature, humidity, and occupancy levels; an energy storage device configured to store excess energy generated by HVAC and lighting systems; and a control algorithm configured to optimize energy consumption based on data from said sensors."
-            },
-            "4567890123": {
-                "abstract": "An electric vehicle with improved range and performance is disclosed. The vehicle comprises a regenerative braking system that converts kinetic energy into electrical energy during braking and a power management system that utilizes the stored energy during acceleration. The regenerative braking system improves the vehicle's overall efficiency and extends its range.",
-                "claims": "An electric vehicle with improved range and performance comprising: a regenerative braking system configured to convert kinetic energy into electrical energy during braking and store said electrical energy in a battery; and a power management system configured to provide said stored electrical energy to an electric motor during acceleration to improve the vehicle's performance and extend its range."
+            "9660732": {
+                "abstract": "It is disclosed an optical coherent receiver for an optical communication network. The optical coherent receiver is configured to receive a modulated optical signal and to process it for generating an in-phase component and a quadrature component. The optical coherent receiver comprises a power adjuster in turn comprising a multiplying unit and a retroactively connected digital circuit. The multiplying unit is configured to multiply the in-phase and quadrature components by in-phase and quadrature gains, respectively, thereby providing power-adjusted in-phase and quadrature components. The digital circuit is configured to compute: a common gain indicative of a sum of the powers of the power-adjusted in-phase and quadrature components; a differential gain indicative of a difference between the powers of the power-adjusted in-phase and quadrature components; and the in-phase and quadrature gains as a product and a ratio, respectively, between the common gain and the differential gain.",
+                "claims": "An optical coherent receiver for an optical communication network, said optical coherent receiver being configured to receive a modulated optical signal and to process said modulated optical signal for generating an in-phase component and a quadrature component, said in-phase component and said quadrature component being electrical signals, said optical coherent receiver comprising a power adjuster in turn comprising: a multiplying unit configured to multiply said in-phase component by an in-phase gain thereby providing a power-adjusted in-phase component, and to multiply said quadrature component by a quadrature gain thereby providing a power-adjusted quadrature component; and a digital circuit connected between output and input of said multiplying unit and configured to compute: a common gain indicative of a sum of a power of said power-adjusted in-phase component and a power of said power-adjusted quadrature component, and a differential gain indicative of a difference between said power of said power-adjusted in-phase component and said power of said power-adjusted quadrature component; and said in-phase gain as a product between said common gain and said differential gain, and said quadrature gain as a ratio between said common gain and said differential gain. 2. An optical coherent receiver according to claim 1, wherein it further comprises an analog-to-digital unit connected at the input of said power adjuster, said analog-to-digital unit being configured to sample said in-phase component and said quadrature component for providing N in-phase component and N quadrature component samples to said power adjuster at each clock cycle of a clock signal generated at said optical coherent receiver, N being an integer equal to or higher than 1. 3. An optical coherent receiver according to claim 2, wherein said multiplying unit is a digital unit configured to multiply said N in-phase component samples by said in-phase gain thereby providing N power-adjusted in-phase component samples, and to multiply said N quadrature component samples by said quadrature gain thereby providing N power-adjusted quadrature component samples. 4. An optical coherent receiver according to claim 1, wherein said multiplying unit is an analog unit. 5. An optical coherent receiver according to claim 4, wherein said power adjuster comprises an analog-to-digital unit connected at the output of said multiplying unit, said analog-to-digital unit being configured to sample said power-adjusted in-phase component and said power-adjusted quadrature component for providing N power-adjusted in-phase component samples and N power-adjusted quadrature component samples at each clock cycle of a clock signal generated at said optical coherent receiver, N being an integer equal to or higher than 1. 6. An optical coherent receiver according to claim 3, wherein said digital circuit comprises a computation module configured to receive said N power-adjusted in-phase component samples and said N power-adjusted quadrature component samples and to calculate a common metric according to the following equation: c = \u2211 k = 0 N - 1 \ue89e \ue89e \uf603 I k \u2032 \uf604 2 + \uf603 Q k \u2032 \uf604 2 , c being said common metric, being said N power-adjusted in-phase component samples and Q\u2032k being said N power-adjusted quadrature component samples. 7. An optical coherent receiver according to claim 3, wherein said digital circuit comprises a computation module configured to receive said N power-adjusted in-phase component samples and said N power-adjusted quadrature component samples and to calculate a common metric according to the following equation: c = \u2211 k = 0 N - 1 \ue89e \ue89e ( \uf603 I k \u2032 \uf604 + \uf603 Q k \u2032 \uf604 2 + ( 1 - 1 2 ) \u00b7 \uf603 \uf603 I k \u2032 \uf604 - \uf603 Q k \u2032 \uf604 \uf604 ) , c being said common metric, I\u2032k being said N power-adjusted in-phase component samples and Q\u2032k being said N power-adjusted quadrature component samples. 8. An optical coherent receiver according to claim 6, wherein said digital circuit further comprises a cascade of an adder, a common multiplier and a common accumulator connected at the output of said computation module, wherein: said adder is configured to calculate c\u22122T, T being a target value that the power of said power-adjusted in-phase component and the power of said power-adjusted quadrature component should reach; said common multiplier is configured to calculate Sc\u00b7(c\u22122T), Sc being a common loop gain; and said common accumulator is configured to update its content (ac[n\u22121]) by adding Sc\u00b7(c\u22122T) to it, thereby providing an updated common content (ac[n]). 9. An optical coherent receiver according to claim 8, wherein said computation module is further configured to calculate a differential metric according to the following equation: d = \u2211 k = 0 N - 1 \ue89e ( \uf603 I k \u2032 \uf604 - \uf603 Q k \u2032 \uf604 ) , d being said differential metric, I\u2032k being said N power-adjusted in-phase component samples and Q\u2032k being said N power-adjusted quadrature component samples. 10. An optical coherent receiver according to claim 9, wherein said digital circuit further comprises a cascade of a differential multiplier and a differential accumulator connected at the output of said computation module, wherein: said differential multiplier is configured to calculate Sd\u00b7d, Sd being a differential loop gain; and said differential accumulator is configured to update its content (ad[n\u22121]) by adding Sd\u00b7d to it, thereby providing an updated differential content (ad[n]). 11. An optical coherent receiver according to claim 10, wherein said differential loop gain is lower than said common loop gain. 12. An optical coherent receiver according to claim 8, wherein said digital circuit further comprises an in-phase adder and a quadrature adder connected both to said common accumulator and to said differential accumulator, wherein: said in-phase adder is configured to provide a sum (ac[n]+ad[n]) of said updated common content (ac[n]) and said updated differential content (ac[n]); and said quadrature adder is configured to provide a difference (ac[n]\u2212ad[n]) between said updated common content (ac[n]) and said updated differential content (ac[n]). 13. An optical coherent receiver according to claim 12, wherein said digital circuit further comprises an in-phase exponential module connected between said in-phase adder and said multiplying unit and a quadrature exponential module connected between said quadrature adder and said multiplying unit, wherein: said in-phase exponential module is configured to calculate said in-phase gain as a negative exponential function of said sum; and said quadrature exponential module is configured to calculate said quadrature gain as a negative exponential function of said difference. 14. A node for a communication network comprising an optical coherent receiver, said optical coherent receiver being configured to receive a modulated optical signal and to process said modulated optical signal for generating an in-phase component and a quadrature component, said in-phase component and said quadrature component being electrical signals, said optical coherent receiver comprising a power adjuster in turn comprising: a multiplying unit configured to multiply said in-phase component by an in-phase gain thereby providing a power-adjusted in-phase component, and to multiply said quadrature component by a quadrature gain thereby providing a power-adjusted quadrature component; and a digital circuit connected between output and input of said multiplying unit and configured to compute: a common gain indicative of a sum of a power of said power-adjusted in-phase component and a power of said power-adjusted quadrature component, and a differential gain indicative of a difference between said power of said power-adjusted in-phase component and said power of said power-adjusted quadrature component; and said in-phase gain as a product between said common gain and said differential gain, and said quadrature gain as a ratio between said common gain and said differential gain. 15. A method for adjusting power of an in-phase component and a quadrature component of a modulated optical signal received at an optical coherent receiver for an optical communication network, said in-phase component and said quadrature component being electrical signals, said method comprising: multiplying said in-phase component by an in-phase gain thereby providing a power-adjusted in-phase component, and multiplying said quadrature component by a quadrature gain thereby providing a power-adjusted quadrature component; and computing: a common gain indicative of a sum of a power of said power-adjusted in-phase component and a power of said power-adjusted quadrature component, and a differential gain indicative of a difference between said power of said power-adjusted in-phase component and said power of said power-adjusted quadrature component; and said in-phase gain as a product between said common gain and said differential gain, and said quadrature gain as a ratio between said common gain and said differential gain."
             },
+            "9782455": {
+                "abstract": "The present invention relates to a method of preparing a peptide comprising the amino acid sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO:1). In particular, the method comprises the steps of providing a first peptide fragment having a first protection group, which peptide fragment is conjugated to a support; providing a second peptide fragment having a second protection group; removing the first protection group from the first peptide fragment; and coupling the second peptide fragment to the N-terminally deprotected, support-conjugated first peptide fragment. The present invention further relates to a method of preparing a pharmaceutical composition containing said peptide.",
+                "claims": "A method of preparing a peptide comprising the amino acid sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO: 1), the method comprising the steps of: (a) providing a first peptide fragment comprising the amino acid sequence X-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO: 2), wherein X is a first protection group and wherein the C-terminal residue of the first peptide fragment is conjugated to a support; (b) providing a second peptide fragment comprising the amino acid sequence Y-His-Gly-Asp-Gly (SEQ ID NO: 3), wherein Y is a second protection group; (c) removing the first protection group from the first peptide fragment; and (d) coupling the second peptide fragment to the N-terminally deprotected, support-conjugated first peptide fragment. 2. The method of claim 1, wherein the first peptide fragment and/or the second peptide fragment are prepared by solid phase peptide synthesis, and wherein optionally, in case the second peptide fragment is prepared by solid phase synthesis, the second peptide fragment is cleaved from the support prior to coupling the second peptide fragment to the N-terminally deprotected first peptide fragment, and/or wherein optionally, in case the first peptide fragment is prepared by solid phase peptide synthesis, the first peptide fragment coupled to the second peptide fragment is cleaved from the support. 3. The method of claim 2, wherein the first peptide fragment and/or the second peptide fragment are provided by conjugating the C-terminal amino acid residue to a support and sequentially adding appropriately protected amino acids to the N-terminus of the C-terminal, support-conjugated residue(s). 4. The method of claim 3, wherein amino acids to be sequentially added to the N-terminus of the C-terminal, support-conjugated residue(s) of the first peptide fragment and/or the second peptide fragment are each protected by a protection group selected from the group consisting of Boc and Fmoc. 5. The method of claim 1, wherein the first protection group is Fmoc. 6. The method of claim 1, wherein the second protection group is an acid-labile protection group, selected from the group consisting of Boc and benzyloxycarbonyl. 7. The method of claim 1, wherein the histidine residue of the second peptide fragment is protected at the side chain with a protection group selected from the group consisting of trityl, Boc, Bom and Bum. 8. The method of claim 1, wherein the aspartic residue of the second peptide fragment is protected at the side chain with a tert-butyl ester protection group. 9. The method of claim 1, comprising: (a) providing by solid phase synthesis a first peptide fragment comprising the amino acid sequence X-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO: 2) by peptide synthesis, wherein X is a Fmoc protection group and wherein the C-terminal residue of the first peptide fragment is conjugated to a support; (b) providing by solid phase synthesis a second peptide fragment comprising the amino acid sequence Y-His-Gly-Asp-Gly (SEQ ID NO: 3) by peptide synthesis, wherein Y is an acid-labile protection group, selected from the group consisting of Boc and benzyloxycarbonyl, and wherein the C-terminal residue of the second peptide fragment is conjugated to a support; (c) cleaving the second peptide fragment from the support; (d) optionally purifying the cleaved second peptide fragment; (e) removing the Fmoc protection group from the first peptide fragment, by adding a secondary amine selected from the group consisting of piperidine, piperazine, morpholine and dicyclohexylamine; (f) coupling the second peptide fragment to the support-conjugated first peptide fragment by adding the purified second peptide fragment to the N-terminally deprotected, support-conjugated first peptide fragment; (g) cleaving the support-conjugated first peptide fragment coupled to the second peptide fragment from the support; and (h) optionally purifying the cleaved first peptide fragment coupled to the second peptide fragment. 10. The method of claim 9, wherein the C-terminal amino acid of the first peptide fragment and/or the second peptide fragment is attached to the functionalized polymer by means of a linker. 11. A method of preparing a pharmaceutical composition containing a peptide comprising the amino acid sequence His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp (SEQ ID NO: 1), the method comprising the steps of: (a) preparing the peptide according to the method of claim 1; and (b) preparing a pharmaceutical composition containing the peptide prepared in step (a). 12. The method of claim 11, wherein the pharmaceutical composition further comprises phosphate buffer in an amount sufficient to adjust the pH of the composition to a physiologically tolerable level. 13. The method of claim 11, wherein the pharmaceutical composition further comprises L-histidine. 14. The method of claim 11, wherein the pharmaceutical composition further comprises a bulking agent selected from the group consisting of mannitol and sucrose. 15. The method of claim 11, wherein the pharmaceutical composition is provided as an injectable dosage form."       },
             "5678901234": {
                 "abstract": "A device for preventing pets from accessing restricted areas is disclosed. The device comprises a motion sensor that detects when a pet enters a restricted area and emits a high-pitched sound to deter the pet from entering. The device is designed to be easily installed and can be used to keep pets away from certain rooms or pieces of furniture.",
                 "claims": "A pet deterrent device comprising: a motion sensor configured to detect when a pet enters a restricted area; and a speaker configured to emit a high-pitched sound to deter said pet from entering said restricted area."